136 related articles for article (PubMed ID: 3438177)
21. A phase II trial of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisolone rapidly alternating with doxorubicin and vincristine (CMFP/AV) in advanced breast cancer.
Rischin D; Bishop JF; Olver IN; Laidlaw CR; Zimet A; Jeal P; Dipell JF
Am J Clin Oncol; 1992 Oct; 15(5):392-4. PubMed ID: 1524039
[TBL] [Abstract][Full Text] [Related]
22. [Use of thymoptin and chemotherapy in the complex treatment of breast cancer].
Skobel'tsyna ES; Gaĭseniuk LA; Kozyreva TV; Kalmykova IIa; Nikiforova NA
Sov Med; 1991; (9):88. PubMed ID: 1798940
[No Abstract] [Full Text] [Related]
23. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
[TBL] [Abstract][Full Text] [Related]
24. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
Levine MN; Bramwell VH; Pritchard KI; Norris BD; Shepherd LE; Abu-Zahra H; Findlay B; Warr D; Bowman D; Myles J; Arnold A; Vandenberg T; MacKenzie R; Robert J; Ottaway J; Burnell M; Williams CK; Tu D
J Clin Oncol; 1998 Aug; 16(8):2651-8. PubMed ID: 9704715
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant therapy of breast cancer: a Southwest Oncology Group experience.
Rivkin SE; Glucksberg H; Foulkes M
Recent Results Cancer Res; 1984; 96():166-74. PubMed ID: 6396770
[No Abstract] [Full Text] [Related]
26. CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus cnf (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: a phase III randomized multicenter study.
Ron IG; Wigler N; Borovik R; Brufman G; Rizel S; Shani A; Brenner J; Farbstein H; Dale A; Inbar MJ; Brenner HJ; Chaitchik S; Catane R
Am J Clin Oncol; 2001 Aug; 24(4):323-7. PubMed ID: 11474254
[TBL] [Abstract][Full Text] [Related]
27. Preoperative chemotherapy in primarily inoperable cancer of the breast.
Luboinski G; Nagadowska M; Pienkowski T
Eur J Surg Oncol; 1991 Dec; 17(6):603-7. PubMed ID: 1743309
[TBL] [Abstract][Full Text] [Related]
28. Randomized trial of cyclophosphamide, methotrexate, and 5-fluorouracil with or without estrogenic recruitment in women with metastatic breast cancer.
Ingle JN; Foley JF; Mailliard JA; Krook JE; Hartmann LC; Jung SH; Veeder MH; Gesme DH; Hatfield AK; Goldberg RM
Cancer; 1994 May; 73(9):2337-43. PubMed ID: 8168039
[TBL] [Abstract][Full Text] [Related]
29. Comparison of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized study.
Cocconi G; Bisagni G; Bella M; Acito L; Anastasi P; Carpi A; Di Costanzo F; Frassoldati A; Mosconi A; Borrini A; Buzzi P
Am J Clin Oncol; 1999 Dec; 22(6):593-600. PubMed ID: 10597744
[TBL] [Abstract][Full Text] [Related]
30. The effects of multiple combination chemotherapy with vincristine, cyclophosphamide (Endoxan), methotrexate, 5-fluorouracil, adriamycin and prednisolone (VEMFAH) for advanced breast cancer.
Kojima T; Hoshino A; Ohara K; Kamiya O; Nagata K; Ito Y; Kinoshita T; Sugiura I; Yamada M; Sato H
Cancer Chemother Pharmacol; 1985; 15(3):268-71. PubMed ID: 3902267
[TBL] [Abstract][Full Text] [Related]
31. Alternating versus sequential therapy in advanced breast cancer.
Romero A; Rabinovich MG; Pérez JE; Macchiavelli M; Leone BA; Strauss E; Goldar D; Alvarez LA; Vallejo C
Medicina (B Aires); 1987; 47(3):243-8. PubMed ID: 3326994
[No Abstract] [Full Text] [Related]
32. [5 years' results of a CMF protocol (methotrexate, cyclophosphamide, fluorouracil) of adjuvant chemotherapy in breast cancers].
Horner-Vallet D; Cappelaere P; Delobelle A; Depadt G; Madelain M; Demaille A
LARC Med; 1984 Nov; 4(9):532-40. PubMed ID: 6549038
[No Abstract] [Full Text] [Related]
33. Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes.
Moliterni A; Bonadonna G; Valagussa P; Ferrari L; Zambetti M
J Clin Oncol; 1991 Jul; 9(7):1124-30. PubMed ID: 2045854
[TBL] [Abstract][Full Text] [Related]
34. The use of a natural history data base to compare outcome among several trials of adjuvant chemotherapy for stage II breast cancer.
Jones SE; Moon TE
Recent Results Cancer Res; 1984; 96():148-54. PubMed ID: 6396768
[No Abstract] [Full Text] [Related]
35. The response to further chemotherapy in patients with carcinoma of the breast who progressed while receiving adjuvant therapy.
Morris DM; Elias EG; Didolkar MS; Brown SD
J Surg Oncol; 1985 Jul; 29(3):154-7. PubMed ID: 3001423
[TBL] [Abstract][Full Text] [Related]
36. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.
Fisher B; Brown AM; Dimitrov NV; Poisson R; Redmond C; Margolese RG; Bowman D; Wolmark N; Wickerham DL; Kardinal CG
J Clin Oncol; 1990 Sep; 8(9):1483-96. PubMed ID: 2202791
[TBL] [Abstract][Full Text] [Related]
37. Vincristine, doxorubicin and mitomycin (VAM) in patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate and fluorouracil (CMF). A clinical trial of the Piedmont Oncology Association (POA).
Shipp SK; Muss HB; Westrick MA; Cooper MR; Jackson DV; Richards FC; White DR; Stuart JJ; Christian RM; Ramseur W
Cancer Chemother Pharmacol; 1983; 11(2):130-3. PubMed ID: 6354509
[TBL] [Abstract][Full Text] [Related]
38. Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan.
Kimura M; Tominaga T; Takatsuka Y; Toi M; Abe R; Koyama H; Takashima S; Nomura Y; Miura S; Kimijima I; Tashiro H; Ohashi Y;
Breast Cancer; 2010 Jul; 17(3):190-8. PubMed ID: 19575284
[TBL] [Abstract][Full Text] [Related]
39. CMF adjuvant programs at the Milan Cancer Institute.
Bonadonna G; Rossi A; Tancini G; Valagussa P; Veronesi U
Recent Results Cancer Res; 1984; 96():66-73. PubMed ID: 6549356
[No Abstract] [Full Text] [Related]
40. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC
J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
